Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

Twenty people died in Japan after receiving Tavneos, a rare disorder therapy developed by Amgen (AMGN), prompting its local partner Kissei (KSPHF) to urge healthcare professionals to exercise caution ...

After the FDA flagged patient deaths linked to Amgen's rare disease drug Tavneos and called for its voluntary removal, the ...

Japanese drugmaker Kissei Pharmaceutical said doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago that clinicians avoid new ...

A Japanese pharmaceutical firm has warned doctors against prescribing a drug for rare autoimmune diseases to new patients following the deaths of 20 people who took it. Kissei Pharmaceutical, which ...

Amgen is standing behind a rare disease drug that the FDA wants off the market due to safety concerns and alleged clinical trial manipulation, and its defense will include a new analysis of the ...

Kissei Pharmaceutical has revised a package insert in Japan for Amgen's rare immune-disease drug Tavneos, saying that serious liver dysfunction could occur. The Japanese pharmaceutical company said ...

April 27 (Reuters) - The U.S. Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, ...

Japanese drugmaker Kissei Pharmaceutical 45470.53%increase; up pointing triangle said doctors in Japan can again prescribe an Amgen AMGN 1.15%increase; up pointing triangle rare-disease drug to new ...

April 27 (Reuters) - The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed withdrawing approval of Amgen's (AMGN.O), opens new tab drug for rare ...